标题
A Molecular Signature Predictive of Indolent Prostate Cancer
作者
关键词
-
出版物
Science Translational Medicine
Volume 5, Issue 202, Pages 202ra122-202ra122
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2013-09-12
DOI
10.1126/scitranslmed.3006408
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer
- (2013) Timothy J. Wilt ANNALS OF INTERNAL MEDICINE
- FGFR1 Is Essential for Prostate Cancer Progression and Metastasis
- (2013) F. Yang et al. CANCER RESEARCH
- Clonal Progression of Prostate Cancers from Gleason Grade 3 to Grade 4
- (2012) A. G. Sowalsky et al. CANCER RESEARCH
- Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study
- (2012) David Olmos et al. LANCET ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
- (2012) J. R. Prensner et al. Science Translational Medicine
- Role of Immediate Confirmatory Prostate Biopsy to Ensure Accurate Eligibility for Active Surveillance
- (2012) Piruz Motamedinia et al. UROLOGY
- survcomp: an R/Bioconductor package for performance assessment and comparison of survival models
- (2011) Markus S. Schröder et al. BIOINFORMATICS
- Active Surveillance for Prostate Cancer: Progress and Promise
- (2011) Matthew R. Cooperberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience
- (2011) Jeffrey J. Tosoian et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study
- (2011) Jack Cuzick et al. LANCET ONCOLOGY
- SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression
- (2011) Zhihu Ding et al. NATURE
- Molecular classification of prostate cancer using curated expression signatures
- (2011) E. K. Markert et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA
- (2011) S. A. Tomlins et al. Science Translational Medicine
- Molecular sampling of prostate cancer: a dilemma for predicting disease progression
- (2010) Andrea Sboner et al. BMC Medical Genomics
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overtreatment of men with low-risk prostate cancer and significant comorbidity
- (2010) Timothy J. Daskivich et al. CANCER
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype
- (2010) Srirupa Roy et al. CELL CYCLE
- Paths of FGFR-driven tumorigenesis
- (2010) Victor D. Acevedo et al. CELL CYCLE
- Molecular genetics of prostate cancer: new prospects for old challenges
- (2010) M. M. Shen et al. GENES & DEVELOPMENT
- Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer
- (2010) Julia H. Hayes et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Overdiagnosis in Cancer
- (2010) H. G. Welch et al. JNCI-Journal of the National Cancer Institute
- Meta-analysis of age-related gene expression profiles identifies common signatures of aging
- (2009) João Pedro de Magalhães et al. BIOINFORMATICS
- Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005
- (2009) H. G. Welch et al. JNCI-Journal of the National Cancer Institute
- Integrating differentiation and cancer: The Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis
- (2008) Cory Abate-Shen et al. DIFFERENTIATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started